Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Regeneron PharmaceuticalsREGN | Open-market sale10b5-1 plan | 05/01 | 05/04 | 100 sh12 trades | $705.24avg. | $70,523.8 | −0.6% | |
Regeneron PharmaceuticalsREGN | Open-market sale10b5-1 plan | 04/01 | 04/03 | 100 sh9 trades | $777.27avg. | $77,727.28 | −0.6% | |
Regeneron PharmaceuticalsREGN | Open-market sale10b5-1 plan | 03/02 | 03/03 | 100 sh13 trades | $785.50avg. | $78,549.55 | −0.6% | |
Regeneron PharmaceuticalsREGN | Open-market sale10b5-1 plan | 02/19 | 02/23 | 1,638 sh11 trades | $781.33avg. | $1,279,811.86 | −49.0% | |
Regeneron PharmaceuticalsREGN | Open-market sale10b5-1 plan | 02/09 | 02/11 | 100 sh13 trades | $778.53avg. | $77,852.6 | −0.6% | |
Regeneron PharmaceuticalsREGN | Open-market sale10b5-1 plan | 02/09 | 02/11 | 2,036 sh11 trades | $778.52avg. | $1,585,058.14 | −32.3% | |
Bonnie L. BasslerDirector | Regeneron PharmaceuticalsREGN | Open-market sale10b5-1 plan | 01/07 | 01/08 | 1,500 sh | $800.00 | $1,200,000 | −46.8% |
Bonnie L. BasslerDirector | Regeneron PharmaceuticalsREGN | Open-market sale10b5-1 plan | 25/11/20 | 25/11/24 | 760 sh | $750.00 | $570,000 | −32.9% |
Jason PitofskyVP Controller | Regeneron PharmaceuticalsREGN | Open-market sale | 25/11/07 | 25/11/10 | 431 sh | $651.43 | $280,766.33 | −9.2% |
Regeneron PharmaceuticalsREGN | Open-market sale | 25/10/29 | 25/10/31 | 6,500 sh6 trades | $654.27avg. | $4,252,745.32 | −73.4% | |
Marion McCourtEVP Commercial | Regeneron PharmaceuticalsREGN | Open-market sale10b5-1 plan | 24/11/01 | 24/11/05 | 1,000 sh | $844.61 | $844,610 | −7.2% |
Regeneron PharmaceuticalsREGN | Open-market sale10b5-1 plan | 24/10/01 | 24/10/03 | 100 sh17 trades | $1,048.78avg. | $104,878.24 | −0.6% | |
Marion McCourtEVP Commercial | Regeneron PharmaceuticalsREGN | Open-market sale10b5-1 plan | 24/10/01 | 24/10/03 | 1,000 sh | $1,054.06 | $1,054,060 | −7.2% |
Regeneron PharmaceuticalsREGN | Open-market sale10b5-1 plan | 24/09/03 | 24/09/05 | 100 sh20 trades | $1,178.68avg. | $117,868.5 | −0.6% | |
Marion McCourtEVP Commercial | Regeneron PharmaceuticalsREGN | Open-market sale10b5-1 plan | 24/09/03 | 24/09/05 | 1,000 sh | $1,178.73 | $1,178,730 | −7.2% |
Regeneron PharmaceuticalsREGN | Open-market sale | 24/08/28 | 24/08/29 | 5,680 sh10 trades | $1,205.33avg. | $6,846,262.22 | −99.6% | |
Regeneron PharmaceuticalsREGN | Open-market sale | 24/08/15 | 24/08/19 | 10,838 sh7 trades | $1,158.17avg. | $12,552,284.5 | −83.3% | |
Bonnie L. BasslerDirector | Regeneron PharmaceuticalsREGN | Open-market sale10b5-1 plan | 24/08/15 | 24/08/19 | 756 sh | $1,170.00 | $884,520 | −35.4% |
Regeneron PharmaceuticalsREGN | Open-market sale10b5-1 plan | 24/08/14 | 24/08/15 | 6,363 sh18 trades | $1,153.15avg. | $7,337,504.87 | −11.6% | |
Regeneron PharmaceuticalsREGN | Open-market sale10b5-1 plan | 24/08/08 | 24/08/12 | 5,197 sh6 trades | $1,084.54avg. | $5,636,346.27 | −9.2% |